Toggle navigation
About Us
Portfolio
News
Contact Us
Lightchain Capital
Recent News
September 26, 2023
NextRNA Therapeutics Strengthens Board of Directors with Appointment of Lori Friedman, PhD
READ MORE
September 09, 2023
Wugen Presents Initial Data from First-in-Human Phase 1/2 Trial of WU-CART-007 at the European Hematology Association (EHA) 2023 Congress
READ MORE
September 06, 2023
Geneoscopy CEO Andrew Barnell to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
READ MORE
September 05, 2023
C4 Therapeutics Announces Chief Financial Officer Succession
READ MORE
August 15, 2023
Wugen Begins First-in-Human Phase 1 Clinical Trial of WU-NK-101, its Lead Allogeneic Memory Natural Killer (NK) Cell Therapy for Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
READ MORE
August 08, 2023
C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
READ MORE
August 08, 2023
AI Proteins Strengthens Leadership with Appointment of Noah D. Beerman as Chief Executive Officer and Industry Leader Mark J. Alles as Chairman of the Board of Directors
READ MORE
August 03, 2023
Closing the Gap: Why Healthcare Needs More Gender Diversity in Leadership
READ MORE
July 20, 2023
Startup Exit Awards 2023: Supercomputer startup SimpleRose raises $23M to bring its technology to market
READ MORE
July 17, 2023
C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
1
2
3
4
5
...
21
Contact Us
Lightchain Capital, LLC
PO Box 31729
St. Louis, MO 63131
Submit
4837,4748,4815,4823,4811,4819,4822,4748,4772,4748,4789,4811,4830,4819,4815,4760,4792,4760,4791,4825,4828,4817,4811,4824,4778,4825,4831,4830,4822,4825,4825,4821,4760,4813,4825,4823,4748,4758,4748,4829,4831,4812,4820,4815,4813,4830,4748,4772,4748,4781,4825,4824,4830,4811,4813,4830,4746,4784,4825,4828,4823,4748,4839
©2021 LIGHTCHAIN CAPITAL, LLC All Rights Reserved |
Privacy Policy
Website by
Tidal Media Group